Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vittorio Loprinzo

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
The Journal of Headache and Pain|December 9, 2025
A phase 4, 24-week, open-label study to evaluate the safety and tolerability of once-daily dosing of 75 mg rimegepant for episodic migraine preventionJeremias Antinew, Robert J Fountaine, Vittorio Loprinzo, et al.
JAMIA Open|May 31, 2024
Using large language models for safety-related table summarization in clinical study reportsRogier Landman, Sean P Healey, Vittorio Loprinzo, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
The Journal of Headache and Pain|December 9, 2025
A phase 4, 24-week, open-label study to evaluate the safety and tolerability of once-daily dosing of 75 mg rimegepant for episodic migraine preventionJeremias Antinew, Robert J Fountaine, Vittorio Loprinzo, et al.
JAMIA Open|May 31, 2024
Using large language models for safety-related table summarization in clinical study reportsRogier Landman, Sean P Healey, Vittorio Loprinzo, et al.
Pageof 1